Key result
Cancer increases the risk of venous thromboembolism two to seven fold, with an incidence of 0.6-7.8% in patients with cancer.
Population
Patients with cancer
Design
Review
Authors
Loading...
Elevated VTE risk in cancer warrants clinical awareness; leaves open refinement of prophylaxis indications in ambulatory settings.
Cancer patients have a significantly elevated risk of VTE and should receive appropriate thromboprophylaxis with UFH or LMWH, especially when hospitalized, undergoing surgery, or receiving active therapy.
Eren et al. (2013) conducted a review in Venous thromboembolism in cancer patients. Cancer vs. Patients without cancer was evaluated on Venous thromboembolism. Cancer increases the risk of venous thromboembolism two to seven fold, with an incidence of 0.6-7.8% in patients with cancer.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: